Keith A. Hruska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keith A. Hruska has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Suresh Mathew
Renal Division, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri, USA
11 shared publicationsToshifumi Sugatani
Renal Division, Department of Pediatrics, Washington University School of Medicine, Saint Louis, Missouri, USA
11 shared publicationsYifu Fang
Renal Division, Department of Pediatrics, Washington University School of Medicine, Saint Louis, Missouri, USA
8 shared publications- Matthew J. Williams
Department of Pediatrics, Nephrology, Washington University in Saint Louis, Saint Louis, Missouri
5 shared publications Richard Lund
Department of Medicine, Creighton University, Omaha, Nebraska, USA
4 shared publicationsCharles Ginsberg
Medicine, Washington University, St. Louis, Missouri
3 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (5) , 955-968
A Western Diet High in Phosphate Primes the Development of the CKD-Mineral Bone Disorder in an Alport Syndrome Model
Key Points: An animal protein high-phosphate diet decreased cardiac mitochondrial oxidative phosphorylation in mice with normal kidney function. The animal-based protein high-phosphate diet worsened the severity of several CKD-mineral bone disease components in CKD. The effects of the diet during normal renal function prime the development and severity of the CKD-mineral bone disease during kidney disease progression. Background: CKD-mineral bone disorder (CKD-MBD) is a syndrome that contributes to cardiovascular mortality. We have shown that CKD decreases cardiac mitochondrial function independent of vascular disease and before cardiac hypertrophy. Hyperphosphatemia, a component of the CKD-MBD occurring in later stages of CKD, has been shown to stimulate vascular calcification (VC). In a mouse model of Alport syndrome CKD resistant to VC, we examine the effects of a high-phosphate Western-type diet (HP) on the components of the CKD-MBD, including cardiac respiration. Methods: Col4a5 -deficient mice and wild-type (WT) littermates were fed an animal protein 1.2% high-phosphate diet or a standard vegetable protein 0.6% phosphate diet. At CKD progression equivalent to human CKD stages 4–5, we examined cardiac tissue for mitochondrial respiration, kidney histology for fibrosis, blood for BUN and CKD-MBD components, kidney tissue for klotho production, and aorta for VC. Results: The HP diet produced hyperphosphatemia in the CKD animals compared with WT. The diet increased plasma parathyroid hormone (PTH; 17-fold), fibroblast growth factor 23 (FGF23) intact (14-fold), and reduced kidney klotho mRNA and protein more than 50%. Alport CKD mice fed the HP diet showed a reduction in cardiac mitochondrial complex 2–mediated oxidative phosphorylation, and higher levels of plasma PTH and FGF23 than CKD mice fed the vegetable protein diet. Comparing WT groups, the HP diet increased PTH and intact FGF23, reduced renal klotho, and decreased cardiac mitochondrial oxidative phosphorylation capacity. VC was not induced by the HP diet. Conclusions: The Western-style high-phosphate diet primed the development of the CKD-MBD in nondiseased animals and worsened the CKD-MBD during CKD progression. Cardiac respiration, renal klotho, FGF23, and PTH are affected by a high-phosphate diet even with normal kidney function, suggesting a need for early intervention in the management of phosphate homeostasis as a component of CKD therapy.
- 2 January 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (5) , 955-968
Open AccessA Western Diet High in Phosphate Primes the Development of the CKD-Mineral Bone Disorder in an Alport Syndrome Model
Key Points: An animal protein high-phosphate diet decreased cardiac mitochondrial oxidative phosphorylation in mice with normal kidney function. The animal-based protein high-phosphate diet worsened the severity of several CKD-mineral bone disease components in CKD. The effects of the diet during normal renal function prime the development and severity of the CKD-mineral bone disease during kidney disease progression. Background: CKD-mineral bone disorder (CKD-MBD) is a syndrome that contributes to cardiovascular mortality. We have shown that CKD decreases cardiac mitochondrial function independent of vascular disease and before cardiac hypertrophy. Hyperphosphatemia, a component of the CKD-MBD occurring in later stages of CKD, has been shown to stimulate vascular calcification (VC). In a mouse model of Alport syndrome CKD resistant to VC, we examine the effects of a high-phosphate Western-type diet (HP) on the components of the CKD-MBD, including cardiac respiration. Methods: Col4a5 -deficient mice and wild-type (WT) littermates were fed an animal protein 1.2% high-phosphate diet or a standard vegetable protein 0.6% phosphate diet. At CKD progression equivalent to human CKD stages 4–5, we examined cardiac tissue for mitochondrial respiration, kidney histology for fibrosis, blood for BUN and CKD-MBD components, kidney tissue for klotho production, and aorta for VC. Results: The HP diet produced hyperphosphatemia in the CKD animals compared with WT. The diet increased plasma parathyroid hormone (PTH; 17-fold), fibroblast growth factor 23 (FGF23) intact (14-fold), and reduced kidney klotho mRNA and protein more than 50%. Alport CKD mice fed the HP diet showed a reduction in cardiac mitochondrial complex 2–mediated oxidative phosphorylation, and higher levels of plasma PTH and FGF23 than CKD mice fed the vegetable protein diet. Comparing WT groups, the HP diet increased PTH and intact FGF23, reduced renal klotho, and decreased cardiac mitochondrial oxidative phosphorylation capacity. VC was not induced by the HP diet. Conclusions: The Western-style high-phosphate diet primed the development of the CKD-MBD in nondiseased animals and worsened the CKD-MBD during CKD progression. Cardiac respiration, renal klotho, FGF23, and PTH are affected by a high-phosphate diet even with normal kidney function, suggesting a need for early intervention in the management of phosphate homeostasis as a component of CKD therapy.
- Open Access
The Impact of a Western Diet High in Phosphate on the CKD-MBD in an Alport Syndrome Model
Background Chronic kidney disease – mineral bone disorder (CKD-MBD) is a syndrome that begins early in CKD, contributes to CKD-associated mortality, and includes components of FGF23 elevation, αklotho deficiency, CKD-stimulated vascular disease, and renal osteodystrophy. Hyperphosphatemia, occurring in later stages of CKD, is also driven by mechanisms of CKD-MBD, and has been shown to stimulate vascular calcification. In a mouse model of Alport CKD that is resistant to vascular calcification, we examine the effects of a high-phosphate Western-type diet on the CKD-MBD, and test whether the diet promotes induction of vascular calcification. Methods An X-linked Col4a5 deficient murine homolog of Alport Syndrome (CKD) and wild type (WT) littermates were fed an animal protein 1.2% high phosphate diet or a standard vegetable protein diet. At disease progression equivalent to CKD stage 4-5, we examined kidney histology for fibrosis, blood for BUN (marker of CKD), and markers of CKD-MBD disease progression, kidney tissue for klotho production, and aorta histology and tissue mRNA and protein analysis for vascular calcification. Results The Western high Pi diet produced hyperphosphatemia in the CKD animals compared to WT and increased plasma PTH (1880 from 110 pg / ml), FGF23 c-term (670 from 120 pg / ml), and FGF23 intact (3780 from 280 pg / ml), and reduced kidney klotho mRNA and protein (57-67% reduction) (all p < 0.01). Referenced against the CKD animals fed vegetable-based diet, the Western high phosphate-fed CKD animals showed higher levels of plasma PTH and FGF23s. In the wild-type control mice with normal renal function, Western diet produced increased PTH, intact FGF23, and reduced renal klotho (all p Conclusions Our results show that a Western-style high-phosphate diet advances elements of the CKD-MBD. Renal klotho, FGF23 and PTH are affected by diet even with normal kidney function, suggesting a need for early intervention in the management of phosphate homeostasis as a component of CKD therapy. Additionally, CKD, klotho, and FGF23 all are associated with early aging. Therefore, our findings suggest that a Western high Pi diet accelerates aging and would contribute to the systemic complications of CKD – cardiac disease, osteodystrophy, and vascular disease.
Open AccessThe Impact of a Western Diet High in Phosphate on the CKD-MBD in an Alport Syndrome Model
Background Chronic kidney disease – mineral bone disorder (CKD-MBD) is a syndrome that begins early in CKD, contributes to CKD-associated mortality, and includes components of FGF23 elevation, αklotho deficiency, CKD-stimulated vascular disease, and renal osteodystrophy. Hyperphosphatemia, occurring in later stages of CKD, is also driven by mechanisms of CKD-MBD, and has been shown to stimulate vascular calcification. In a mouse model of Alport CKD that is resistant to vascular calcification, we examine the effects of a high-phosphate Western-type diet on the CKD-MBD, and test whether the diet promotes induction of vascular calcification. Methods An X-linked Col4a5 deficient murine homolog of Alport Syndrome (CKD) and wild type (WT) littermates were fed an animal protein 1.2% high phosphate diet or a standard vegetable protein diet. At disease progression equivalent to CKD stage 4-5, we examined kidney histology for fibrosis, blood for BUN (marker of CKD), and markers of CKD-MBD disease progression, kidney tissue for klotho production, and aorta histology and tissue mRNA and protein analysis for vascular calcification. Results The Western high Pi diet produced hyperphosphatemia in the CKD animals compared to WT and increased plasma PTH (1880 from 110 pg / ml), FGF23 c-term (670 from 120 pg / ml), and FGF23 intact (3780 from 280 pg / ml), and reduced kidney klotho mRNA and protein (57-67% reduction) (all p < 0.01). Referenced against the CKD animals fed vegetable-based diet, the Western high phosphate-fed CKD animals showed higher levels of plasma PTH and FGF23s. In the wild-type control mice with normal renal function, Western diet produced increased PTH, intact FGF23, and reduced renal klotho (all p Conclusions Our results show that a Western-style high-phosphate diet advances elements of the CKD-MBD. Renal klotho, FGF23 and PTH are affected by diet even with normal kidney function, suggesting a need for early intervention in the management of phosphate homeostasis as a component of CKD therapy. Additionally, CKD, klotho, and FGF23 all are associated with early aging. Therefore, our findings suggest that a Western high Pi diet accelerates aging and would contribute to the systemic complications of CKD – cardiac disease, osteodystrophy, and vascular disease.
- 1 May 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 326 (5) , F751-F767
In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy
Heart disease is an important morbidity of chronic kidney disease (CKD). Hypertension, vascular stiffness, and vascular calcification all contribute to cardiac pathophysiology. However, cardiac function in CKD devoid of vascular disease has not been studied. Here, in an animal model of human CKD without conduit arterial disease, we analyze cardiac respiration and discover that CKD directly impairs cardiac mitochondrial function by decreasing oxidative phosphorylation. Protection of cardiac oxidative phosphorylation may be a therapeutic target in CKD.
- 1 May 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 326 (5) , F751-F767
In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy
Heart disease is an important morbidity of chronic kidney disease (CKD). Hypertension, vascular stiffness, and vascular calcification all contribute to cardiac pathophysiology. However, cardiac function in CKD devoid of vascular disease has not been studied. Here, in an animal model of human CKD without conduit arterial disease, we analyze cardiac respiration and discover that CKD directly impairs cardiac mitochondrial function by decreasing oxidative phosphorylation. Protection of cardiac oxidative phosphorylation may be a therapeutic target in CKD.
- 1 April 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (4) , 520-523
Acidosis in CKD May Affect Mineralization of Newly Formed Bone According to HR-pQCT and Quantitative Back Scatter Electron Imaging
- 1 April 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (4) , 520-523
Acidosis in CKD May Affect Mineralization of Newly Formed Bone According to HR-pQCT and Quantitative Back Scatter Electron Imaging
- Open Access
- 26 January 2023
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 14, 1120308
Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone—Vascular paradox, a therapeutic target, and a biomarker
The chronic kidney disease-mineral bone disorder (CKD-MBD) is a complex multi-component syndrome occurring during kidney disease and its progression. Here, we update progress in the components of the syndrome, and synthesize recent investigations, which suggest a potential mechanism of the bone-vascular paradox. The discovery that calcified arteries in chronic kidney disease inhibit bone remodeling lead to the identification of factors produced by the vasculature that inhibit the skeleton, thus providing a potential explanation for the bone-vascular paradox. Among the factors produced by calcifying arteries, sclerostin secretion is especially enlightening. Sclerostin is a potent inhibitor of bone remodeling and an osteocyte specific protein. Its production by the vasculature in chronic kidney disease identifies the key role of vascular cell osteoblastic/osteocytic transdifferentiation in vascular calcification and renal osteodystrophy. Subsequent studies showing that inhibition of sclerostin activity by a monoclonal antibody improved bone remodeling as expected, but stimulated vascular calcification, demonstrate that vascular sclerostin functions to brake the Wnt stimulation of the calcification milieu. Thus, the target of therapy in the chronic kidney disease-mineral bone disorder is not inhibition of sclerostin function, which would intensify vascular calcification. Rather, decreasing sclerostin production by decreasing the vascular osteoblastic/osteocytic transdifferentiation is the goal. This might decrease vascular calcification, decrease vascular stiffness, decrease cardiac hypertrophy, decrease sclerostin production, reduce serum sclerostin and improve skeletal remodeling. Thus, the therapeutic target of the chronic kidney disease-mineral bone disorder may be vascular osteoblastic transdifferentiation, and sclerostin levels may be a useful biomarker for the diagnosis of the chronic kidney disease-mineral bone disorder and the progress of its therapy.
- 26 January 2023
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 14, 1120308
Open AccessUpdates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone—Vascular paradox, a therapeutic target, and a biomarker
The chronic kidney disease-mineral bone disorder (CKD-MBD) is a complex multi-component syndrome occurring during kidney disease and its progression. Here, we update progress in the components of the syndrome, and synthesize recent investigations, which suggest a potential mechanism of the bone-vascular paradox. The discovery that calcified arteries in chronic kidney disease inhibit bone remodeling lead to the identification of factors produced by the vasculature that inhibit the skeleton, thus providing a potential explanation for the bone-vascular paradox. Among the factors produced by calcifying arteries, sclerostin secretion is especially enlightening. Sclerostin is a potent inhibitor of bone remodeling and an osteocyte specific protein. Its production by the vasculature in chronic kidney disease identifies the key role of vascular cell osteoblastic/osteocytic transdifferentiation in vascular calcification and renal osteodystrophy. Subsequent studies showing that inhibition of sclerostin activity by a monoclonal antibody improved bone remodeling as expected, but stimulated vascular calcification, demonstrate that vascular sclerostin functions to brake the Wnt stimulation of the calcification milieu. Thus, the target of therapy in the chronic kidney disease-mineral bone disorder is not inhibition of sclerostin function, which would intensify vascular calcification. Rather, decreasing sclerostin production by decreasing the vascular osteoblastic/osteocytic transdifferentiation is the goal. This might decrease vascular calcification, decrease vascular stiffness, decrease cardiac hypertrophy, decrease sclerostin production, reduce serum sclerostin and improve skeletal remodeling. Thus, the therapeutic target of the chronic kidney disease-mineral bone disorder may be vascular osteoblastic transdifferentiation, and sclerostin levels may be a useful biomarker for the diagnosis of the chronic kidney disease-mineral bone disorder and the progress of its therapy.
- 31 March 2020
- Published by Elsevier
- p. 43-56
Pathophysiology of The Chronic Kidney Disease–Mineral Bone Disorder
- 31 March 2020
- Published by Elsevier
- p. 43-56
Pathophysiology of The Chronic Kidney Disease–Mineral Bone Disorder
- Open Access
- 1 November 2019
- Published by Elsevier in Kidney International Reports
- Vol. 4 (11) , 1585-1597
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification
- 1 November 2019
- Published by Elsevier in Kidney International Reports
- Vol. 4 (11) , 1585-1597
Open AccessSotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification
- 1 February 2019
- Published by Elsevier in Kidney International
- Vol. 95 (2) , 261-263
New pathogenic insights inform therapeutic target development for renal osteodystrophy
- 1 February 2019
- Published by Elsevier in Kidney International
- Vol. 95 (2) , 261-263
New pathogenic insights inform therapeutic target development for renal osteodystrophy
- Open Access
- 1 September 2018
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 11 (9)
Correction: Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis (doi: 10.1242/dmm.030130)
There was an error published in Dis. Model. Mech. 10, 1371-1379 (doi: 10.1242/dmm.030130).
- 1 September 2018
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 11 (9)
Open AccessCorrection: Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis (doi: 10.1242/dmm.030130)
There was an error published in Dis. Model. Mech. 10, 1371-1379 (doi: 10.1242/dmm.030130).